

# Changes in health in England, with analysis by English regions and areas of deprivation, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013



John N Newton†, Adam D M Briggs, Christopher J L Murray, Daniel Dicker, Kyle J Foreman, Haidong Wang, Mohsen Naghavi, Mohammad H Forouzanfar, Summer Lockett Ohno, Ryan M Barber, Theo Vos, Jeffrey D Stanaway, Jürgen C Schmidt, Andrew J Hughes, Derek F J Fay, Russell Ecob, Charis Gresser, Martin McKee, Harry Rutter, Ibrahim Abubakar\*, Raghil Ali\*, H Ross Anderson\*, Amitava Banerjee\*, Derrick A Bennett\*, Eduardo Bernabé\*, Kamaldeep S Bhui\*, Stanley M Biryukov\*, Rupert R Bourne\*, Carol E G Brayne\*, Nigel G Bruce\*, Traolach S Brugha\*, Michael Burch\*, Simon Capewell\*, Daniel Casey\*, Rajiv Chowdhury\*, Matthew M Coates\*, Cyrus Cooper\*, Julia A Critchley\*, Paul I Dargan\*, Mukesh K Dherani\*, Paul Elliott\*, Majid Ezzati\*, Kevin A Fenton\*, Maya S Fraser\*, Thomas Fürst\*, Felix Greaves\*, Mark A Green\*, David J Gunnell\*, Bernadette M Hannigan\*, Roderick J Hay\*, Simon I Hay\*, Harry Hemingway\*, Heidi J Larson\*, Katharine J Looker\*, Raimundas Lunevicius\*, Ronan A Lyons\*, Wagner Marcenes\*, Amanda J Mason-Jones\*, Fiona E Matthews\*, Henrik Moller\*, Michele E Murdoch\*, Charles R Newton\*, Neil Pearce\*, Frédéric B Piel\*, Daniel Pope\*, Kazem Rahimi\*, Alina Rodriguez\*, Peter Scarborough\*, Austin E Schumacher\*, Ivy Shiu\*, Liam Smeeth\*, Alison Tedstone\*, Jonathan Valabhji\*, Hywel C Williams\*, Charles D A Wolfe\*, Anthony D Woolf\*, Adrian C J Davis

## Summary

**Background** In the Global Burden of Disease Study 2013 (GBD 2013), knowledge about health and its determinants has been integrated into a comparable framework to inform health policy. Outputs of this analysis are relevant to current policy questions in England and elsewhere, particularly on health inequalities. We use GBD 2013 data on mortality and causes of death, and disease and injury incidence and prevalence to analyse the burden of disease and injury in England as a whole, in English regions, and within each English region by deprivation quintile. We also assess disease and injury burden in England attributable to potentially preventable risk factors. England and the English regions are compared with the remaining constituent countries of the UK and with comparable countries in the European Union (EU) and beyond.

**Methods** We extracted data from the GBD 2013 to compare mortality, causes of death, years of life lost (YLLs), years lived with a disability (YLDs), and disability-adjusted life-years (DALYs) in England, the UK, and 18 other countries (the first 15 EU members [apart from the UK] and Australia, Canada, Norway, and the USA [EU15+]). We extended elements of the analysis to English regions, and subregional areas defined by deprivation quintile (deprivation areas). We used data split by the nine English regions (corresponding to the European boundaries of the Nomenclature for Territorial Statistics level 1 [NUTS 1] regions), and by quintile groups within each English region according to deprivation, thereby making 45 regional deprivation areas. Deprivation quintiles were defined by area of residence ranked at national level by Index of Multiple Deprivation score, 2010. Burden due to various risk factors is described for England using new GBD methodology to estimate independent and overlapping attributable risk for five tiers of behavioural, metabolic, and environmental risk factors. We present results for 306 causes and 2337 sequelae, and 79 risks or risk clusters.

**Findings** Between 1990 and 2013, life expectancy from birth in England increased by 5·4 years (95% uncertainty interval 5·0–5·8) from 75·9 years (75·9–76·0) to 81·3 years (80·9–81·7); gains were greater for men than for women. Rates of age-standardised YLLs reduced by 41·1% (38·3–43·6), whereas DALYs were reduced by 23·8% (20·9–27·1), and YLDs by 1·4% (0·1–2·8). For these measures, England ranked better than the UK and the EU15+ means. Between 1990 and 2013, the range in life expectancy among 45 regional deprivation areas remained 8·2 years for men and decreased from 7·2 years in 1990 to 6·9 years in 2013 for women. In 2013, the leading cause of YLLs was ischaemic heart disease, and the leading cause of DALYs was low back and neck pain. Known risk factors accounted for 39·6% (37·7–41·7) of DALYs; leading behavioural risk factors were suboptimal diet (10·8% [9·1–12·7]) and tobacco (10·7% [9·4–12·0]).

**Interpretation** Health in England is improving although substantial opportunities exist for further reductions in the burden of preventable disease. The gap in mortality rates between men and women has reduced, but marked health inequalities between the least deprived and most deprived areas remain. Declines in mortality have not been matched by similar declines in morbidity, resulting in people living longer with diseases. Health policies must therefore address the causes of ill health as well as those of premature mortality. Systematic action locally and nationally is needed to reduce risk exposures, support healthy behaviours, alleviate the severity of chronic disabling disorders, and mitigate the effects of socioeconomic deprivation.

**Funding** Bill & Melinda Gates Foundation and Public Health England.

**Copyright** © Newton et al. Open Access article distributed under the terms of CC BY.

*Lancet* 2015; 386: 2257–74

Published Online

September 15, 2015

[http://dx.doi.org/10.1016/S0140-6736\(15\)00195-6](http://dx.doi.org/10.1016/S0140-6736(15)00195-6)

See [Comment](#) page 2232

\*Authors listed alphabetically

†Corresponding author

Public Health England, London, UK (Prof I Abubakar FRCP, Prof A C J Davis PhD, R Ecob MSc, D F J Fay MSc, K A Fenton MD, F Greaves PhD, C Gresser MSc, B M Hannigan PhD, A J Hughes MSc, Prof J N Newton FRCP, J C Schmidt Dott Med, A Tedstone PhD); London School of Economics, London, UK (Prof A C J Davis); Institute for Health Metrics and Evaluation, Seattle, WA, USA (Prof S I Hay DSc, H J Larson PhD, Prof C J L Murray DPhil, D Dicker BS, K J Foreman MPH, H Wang PhD, M Naghavi PhD, M H Forouzanfar PhD, S Lockett Ohno BA, R M Barber BS, T Vos PhD, J D Stanaway PhD, A E Schumacher BS, M S Fraser BA, M M Coates BS, S M Biryukov BS, D Casey BA); University of Manchester, Manchester, UK (Prof J N Newton); Centre for Infectious Disease Epidemiology and MRC Clinical Trials Unit, London, UK (Prof I Abubakar); INDOX Cancer Research Network, Oxford, UK (R Ali FRCP); John Radcliffe Hospital, Oxford, UK (R Ali); Green-Templeton College, University of Oxford, Oxford, UK (R Ali); Population Health

Research Institute, Hamilton, ON, Canada (Prof H R Anderson MD); MRC-PHE Centre for Environment and Health, London, UK (Prof H R Anderson); St George's, University of London, London, UK (Prof H R Anderson, Prof J A Critchley DPhil); University of Birmingham, Birmingham, UK (A Banerjee DPhil); Clinical Trials Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK (D A Bennett PhD); King's College London Dental Institute, London, UK (E Bernabé PhD); Wolfson Institute of Preventive Medicine, Barts & The London School of Medicine, Queen Mary University of London, London, UK (Prof K S Bhuvi FRCPsych); Vision & Eye Research Unit, Anglia Ruskin University, Cambridge, UK (Prof R R Bourne FRCOphth); Cambridge Institute of Public Health, University of Cambridge, Cambridge, UK (Prof C E G Brayne MD, F E Matthews PhD); University of Oxford, Oxford, UK (A D M Briggs MRCP, C R Newton MD, F B Piel PhD); University of Liverpool, Liverpool, UK (N G Bruce PhD, M K Dherani PhD, R Lunevicius MD, D Pope PhD, Prof S Capewell DSC); University of Leicester, Leicester, UK (Prof T S Brugha MD); Great Ormond Street Hospital for Children, London, UK (M Burch MD); University of Cambridge, Cambridge, UK (R Chowdhury PhD); MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK (Prof C Cooper FMedSci); Guy's and St Thomas' NHS Foundation Trust, London, UK (P I Dargan FRCP); University College London, London, UK (Prof A C J Davis, Prof H Hemingway FRCP); Department of Epidemiology and Biostatistics, MRC-PHE Centre for Environment and Health, Imperial College London, London, UK (Prof P Elliott PhD, Prof A Rodriguez PhD); MRC-PHE Centre for Population Health, School of Public Health, Imperial College London,

## Research in context

### Evidence before this study

Responsibility for health and public health has been devolved to the constituent countries of the UK since 1998, but no single accessible source describing disease burden by cause in England exists. A published estimate of burden of disease for the UK, using GBD 2010 data and methodology, has been widely used by policy makers but has limitations and needs updating. Routine mortality statistics show progressive improvements in life expectancy, but inequalities persist between countries in the UK and regions within England. Routine measures of morbidity are not reported in a way that allow direct comparisons of burden between causes at a national or regional level. Attributable risks have been calculated for some causes (eg, smoking and air pollution) and for some disorders (eg, cancers) but are not available in a comprehensive framework covering multiple risks and diseases. Relevant literature reviews were undertaken to inform components of the GBD analysis in particular on the relation between risk factors and outcomes.

### Added value of this study

The GBD 2013 analysis of causes of death, disease, and injury incidence and prevalence, YLDs, and risk factors is a major update and improvement in the evidence base underlying the quantification of comparable disease and risk factor estimates compared with the most recent GBD analyses in 2010. For the

first time, GBD results for England are quantified at the national and subnational level (at the level of nine English regions) and by IMD-2010 deprivation quintile using a range of routine and published data sources.

### Implications

Quantification of the continuing burden of preventable ill health in England more than justifies recent calls for a "radical upgrade in prevention and public health". A huge opportunity exists for preventive public health: if levels of health in the worst performing regions in England matched the best performing ones, England would have one of the lowest burdens of disease of any advanced industrialised country. The scale of the increasing level of disability suggests the need for new, more integrated models of care spanning health and social services that respond to the specific needs and circumstances of individual patients. Inequalities in health are greater within English regions than between them and are therefore largely related to deprivation, not geography. The causes of inequalities need to be addressed wherever they occur. The importance of prevention argues for investment in robust, standardised comparative assessments of the cost-effectiveness of different public health policies to aid decision making, akin to those used in England for health technologies.

## Introduction

The Global Burden of Disease (GBD) project is a worldwide exercise to integrate the widest possible range of reliable knowledge about health and its determinants into a universal health framework. Outputs allow meaningful comparisons between countries and over time, and quantify the contributions of different diseases and risk factors to overall burden.

Investigators of a previous GBD study<sup>1</sup> used data from 2010 to compare the UK with a group of other countries. The new analysis reported here uses data from 1990 through 2013 and focuses on England. Responsibility for health and public health has been devolved to the constituent countries of the UK (England, Scotland, Wales, and Northern Ireland) since 1998,<sup>2</sup> so this geographical level of analysis is most meaningful. We compare England and the English regions with the remaining constituent countries of the UK, and with comparable countries in the European Union (EU) and beyond. This study comes at a time when both national and local health-policy makers are reviewing and reassessing priorities for action in the light of financial pressures. The potential for prevention and public health to secure improved population health and reduce demand on England's National Health Service (NHS) has also received further attention recently.<sup>3</sup>

The Global Burden of Diseases, Injuries, and Risk Factors Study 2013 (GBD 2013) provides both improvements in data and advances in methodology compared with previous versions of the GBD.<sup>4,7</sup> These advances include a greatly

improved approach to identification of the contribution of various risk factors and combinations of risks, as explained in the Methods and reported in detail elsewhere,<sup>6</sup> as well as updates to many data sources.

The subnational analysis reported here, based on English regions and areas within them that have differing levels of deprivation, makes it possible to map disease burden according to socioeconomic determinants of health. This report therefore not only uses an improved approach but also extends the scope of earlier work and increases its relevance to policy makers in several ways.

## Methods

### Overview

Here we use data from the GBD 2013 study of causes of death, disease, and injury incidence and prevalence as well as years lived with disability (YLDs) to analyse the burden of diseases and injuries in England by English region and, within each English region by deprivation quintile (defined nationally). The methods employed in the GBD 2013, including the systematic approach to collating cause of death from different countries, the mapping across different revisions and national variants of the International Classification of Diseases and Injuries (ICD), redistribution of deaths assigned to so-called garbage codes, and the cause of death modelling approach used for each cause, have been described in detail elsewhere.<sup>4</sup> The GBD 2013 Collaborators<sup>5</sup> describe the data and methods used to

estimate incidence, prevalence, and YLDs for 306 causes and 2337 sequelae from 1990 to 2013, a substantial increase from 220 causes and 1160 sequelae in the GBD 2010 analysis.<sup>1</sup> This GBD 2013 paper includes a description of the systematic reviews of the published literature, identification of unpublished data sources, efforts to map data to a consistent set of case definitions, and the general approach to Bayesian meta-regression using DisMod-MR 2.0, which allows the estimation of incidence, prevalence, remission, excess mortality, and cause-specific mortality rates that are internally consistent. Details of the method, the likelihood used in estimation, and the source code have been published elsewhere.<sup>8,9</sup> The analysis of risk factor-attributable burden uses the GBD 2013 framework and results.<sup>6</sup> Sampling and non-sampling error as well as model uncertainty is propagated by estimating all steps in the calculations 1000 times. 95% uncertainty intervals (UIs) are presented by the 2·5 and 97·5 centile values.

Another new feature of the GBD 2013 study is the systematic aggregation of the burden attributed to five tiers of risk factors: the first tier is all GBD risks combined; the second tier consists of three large categories of metabolic, behavioural, and environmental and occupational risks; the third tier contains single risks, such as high blood pressure, and risk clusters, such as child and maternal under-nutrition or air pollution; the fourth tier includes single risks within such clusters, such as vitamin A deficiency or household air pollution; and the fifth tier is for individual occupational carcinogens or the division of childhood underweight into stunting, underweight, and wasting. At each level of the hierarchy, a decision is made whether the combined effects are independent and can be added, whether they are joint effects best represented by multiplication, or whether they share common pathways for which mediation needs to be taken into account. For each aggregation, the proportion of the effect shared with another risk or combination of risks can thus be made explicit, using modified Venn diagrams that show the overlaps between metabolic, behavioural, and environmental and occupational risks.

Here we focus on specific issues related to the analysis of causes of death, injury incidence and prevalence, and risk factor prevalence in England, the nine English regions, and 45 subregional areas defined by deprivation quintile (deprivation areas).

### Division of England into English regions and deprivation areas

Estimates of disease burden have been created for the nine English regions, as defined by the former government office regions in England, and correspond to the European boundaries of the Nomenclature for Territorial Statistics level 1 (NUTS 1) regions. In a further refinement, all English lower super output areas, relatively homogeneous areas containing about

1600 people on average,<sup>10</sup> were ranked nationally using the Index of Multiple Deprivation (IMD-2010) and allocated to quintiles. The IMD-2010 is a composite measure estimated at a small geographical area and includes seven domains: income, employment, health and disability, education, skills and training, barriers to housing and services, living environment, and crime.<sup>11</sup> The health and disability domain of the IMD-2010 contributes 13·5% to the score and encompasses four measures: years of potential life lost, comparative illness and disability ratio, rate of emergency admissions to hospital, and proportion of adults younger than 60 years who have mood or anxiety disorders. Although inevitably partially correlated with health, exclusion of the health component from an earlier version of the IMD has been shown to make little difference to ranking of areas by deprivation in practice.<sup>12</sup> The lower super output areas in each quintile were then reallocated to their region, thereby dividing each of the nine English regions into five deprivation groups, or 45 regional deprivation areas in total. As the lower super output areas at each level of deprivation are unevenly distributed among the English regions, there will be a greater share of the regional population living in the most deprived and least deprived (nationally) areas in each English region. Thus, the proportion of the population in the most deprived group ranges from 7·3% in South East England to 32·8% in North West England. For the least deprived group, this proportion ranges from 7·9% in Greater London to 34·8% in South East England. The complete breakdown of these proportions is provided in the appendix (p 4). Within each English region, the most deprived area is referred to as deprivation level 1, and the least deprived area as deprivation level 5.

Mortality data for England from 1990 to 2012, available from the Office for National Statistics, were split into regional and deprivation groups based on the postcode of residence. Where a postcode for the deceased had not been provided, these deaths were discarded from the analysis of England mortality because no residence in England was assumed. These records make up less than 0·3% of all mortality records. Each death was assigned to a lower super output area, deprivation group, and English region on the basis of the person's postcode. GBD estimation of disease prevalence and incidence also makes use of social, cultural, economic, and environmental covariates; some covariate and morbidity data were available at the level of English region. The source data for England used at each level are provided in the appendix p 5; regional level covariates that have been included are listed in the appendix p 44.

### Analysis of cause of death by English region and deprivation area

As outlined in the GBD 2013 report about global mortality and cause of death,<sup>4</sup> vital registration data covering the years 1980 to 2012 were analysed at the

London, UK (Prof M Ezzati FMedSci); Department of Infectious Disease Epidemiology, Imperial College London, London, UK (T Fürst PhD); Department of Primary Care and Public Health, Imperial College London, London, UK (F Greaves); School of Health and Related Research (SchARR), University of Sheffield, Sheffield, UK (M A Green PhD); School of Social and Community Medicine, University of Bristol, Bristol, UK (Prof D J Gunnell DSc); Ulster University, Coleraine, Northern Ireland (B M Hannigan); International Foundation for Dermatology, London, UK (Prof R J Hay DM); Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK (Prof S I Hay); Farr Institute of Health Informatics Research, London, UK (Prof H Hemingway, Prof L Smeeth FRCGP); Department of Infectious Disease Epidemiology (H J Larson) and Department of Health Services Research and Policy (M McKee DSc), London School of Hygiene & Tropical Medicine, London, UK; School of Social and Community Medicine, University of Bristol, Bristol, UK (K J Looker PhD); Aintree University Hospital NHS Foundation Trust, University of Liverpool, Liverpool, UK (R Lunevicius); Queen Mary University of London (Prof W Marcesnes PhD); Department of Health Sciences, University of York, York, UK (A J Mason-Jones PhD); Adolescent Health Research Unit, University of Cape Town, Cape Town, South Africa (A J Mason-Jones); Institute of Health and Society, Newcastle University, Newcastle, UK (F E Matthews); Cancer Epidemiology and Population Health, King's College London, London, UK (Prof H Moller DuMed); West Hertfordshire Hospitals NHS Trust, Hertfordshire, UK (M E Murdoch FRCP); London School of Hygiene & Tropical Medicine (Prof N Pearce PhD, H Rutter MB Mchir, Prof L Smeeth); George Institute for Global Health and Division of Cardiovascular Medicine, Oxford Martin School, University of Oxford, Oxford, UK (K Rahimi DM);

NHS England, Leeds, UK (Prof J Valabhji MD); Imperial College Healthcare NHS Trust, London, UK (Prof J Valabhji); Imperial College London, London, UK (Prof J Valabhji); University of Edinburgh, Edinburgh, Scotland (I Shiu Phd); University of Nottingham, Nottingham, UK (Prof H C Williams DSc); King's College London, London, UK (Prof C D A Wolfe MD); Royal Cornwall Hospital, Treliske, UK (Prof A D Woolf MBBS); Mid Sweden University, Sundsvall, Sweden (Prof A Rodriguez); British Heart Foundation Centre on Population Approaches for NCD Prevention, University of Oxford, Oxford, UK (P Scarborough DPhil); Northumbria University, Newcastle upon Tyne (I Shiu); and Farr Institute, College of Medicine, Swansea University, Swansea, UK (Prof R A Lyons MD)

Correspondence to: Prof John Newton, Public Health England, Wellington House, London SE1 8UG, UK [john.newton@phe.gov.uk](mailto:john.newton@phe.gov.uk)

For the Global Burden of Disease IHME home page see <http://www.healthdata.org/gbd>

For the Eurostat NUTS classification see <http://ec.europa.eu/eurostat/web/nuts>

See Online for appendix

For Cause of death data for each observation, before redistribution, post-redistribution, and the results of modelling see <http://vizhub.healthdata.org/cod/>

regional level. Registration of deaths that happen in England is a legal requirement, and because registration is necessary before disposal of the body, mortality data are assumed to be complete.<sup>1,13,14</sup> We reclassified causes of death for deaths assigned to causes that cannot or should not be an underlying cause of death, so-called garbage codes.<sup>15,16</sup> Standard GBD 2013 redistribution of garbage-code algorithms was applied.<sup>17</sup> Although data were available for all years between 1980 and 2012, to deal with stochastic variation at the regional level, while following the GBD 2013 methods, we modelled causes of death using cause of death ensemble modelling (CODEm).<sup>4,18</sup> CODEm has been used extensively to model causes of death; an ensemble model is developed by testing the performance of a wide array of models (mixed effects or space-time Gaussian process regression), different measures of mortality (rates or cause fractions) and varying combinations of covariates (drawing on a database created for GBD of more than 200 diverse characteristics for countries over time, such as gross domestic product, level of education, dietary factors, use of health-service, and environmental statistics), and by selecting the models with best out-of-sample performance. For example, GBD suicide estimates for the UK are lower than those produced by the Office for National Statistics by almost a quarter. The Office for National Statistics estimates include all deaths coded as suicide (ICD-10 X60–X84) and deaths coded as due to injury and poisoning of undetermined intent (ICD Y10–34),<sup>19</sup> whereas GBD uses a redistribution approach, coding only a proportion of undetermined intent deaths as suicide.

The GBD places disease categories within a four-level cause hierarchy. The first level divides causes into communicable diseases, non-communicable diseases, and injuries; the second level consists of major disease or injury groups, such as cardiovascular diseases or transport injuries; the third level (at which most results are reported) further subdivides causes into disease or injury types, such as cerebrovascular disease or road injuries; and a final fourth level subdivides those disease types where appropriate. Further details can be found in the supplementary appendix of the GBD 2013 Mortality and Cause of Death report.<sup>4</sup>

Tabulations of deaths by cause were generated by deprivation area within each English region. Where the causes of deaths were identified as garbage codes, these were reclassified using the GBD 2013 algorithms. Owing to small sample size in some age–sex–cause groups, we sought to smooth stochastic variation over time. To estimate causes of death by age, sex, and year for a deprivation area within each English region, we first computed the fraction of deaths for a cause–sex–age–year in each deprivation area. To minimise the effect of stochastic fluctuations on the results, we used a 3-year moving average for age groups over 15 years, and a 5-year moving average for age groups under 15 years. We chose

a longer time period for the moving average for childhood age groups because these data are most prone to fluctuations due to small numbers of annual deaths. Moving-average deprivation-area fractions within a cause–age–sex–year group were rescaled so that the sum of cause fractions equalled 100%. These deprivation-area fractions were multiplied by the regional level final estimates of death counts for an age–sex–year group for a given cause to generate estimates of final death counts for each deprivation area. Death counts were divided by deprivation area population to generate deprivation-level cause–age–sex–year rates.

### Disease and injury incidence, prevalence, and YLDs by English region and deprivation area

A list of sources used for the analysis of non-fatal health outcomes in England organised by disease is provided in the appendix (p 5). These sources include studies extracted from the published literature through the GBD systematic reviews as well as extractions from surveys, such as the Health Survey for England,<sup>20</sup> and administrative sources, such as NHS hospital discharge data. We also used new data from the UK-based Cognitive Function and Ageing Studies.<sup>21</sup> Most disease sequelae have been modelled in GBD 2013 using a Bayesian meta-regression method, DisMod-MR 2.0, in which each English region has been analysed as a distinct geographic unit. A prior for the Bayesian meta-regression is calculated for each English region using the data for all countries in western Europe, with random effects on countries and English regions and fixed effects that vary by the disease being modelled.

To analyse injuries, we made use of both the external cause of injury and the nature of injury. As detailed elsewhere,<sup>5</sup> we used survey and hospital activity data to estimate incidence of injuries for which hospital admission was necessary and injuries for which hospital admission was not necessary. Hospital data dual-coded to nature of injury and external cause of injury were used to estimate the fraction of each injury with different types of disabling sequelae. Cohort studies from four countries were used to estimate the probability of long-term disability for each type of injury.<sup>6,22,23</sup> DisMod-MR 2.0 was used to estimate the prevalence of injury in each birth cohort on the basis of long-term disability arising from past incidence. Given the absence of data on injury incidence before 1980, we assumed that age-specific incidence in cohorts before 1980 was equal to the rate in 1980.

Following the GBD 2013 methods, prevalence of individuals in each sequela was multiplied by the disability weight for the corresponding health state to calculate YLDs for the particular sequela. The sum of all the YLDs for relevant sequelae is the overall YLD for each disease. We based disability weights on the responses by the general public to questions about which health state of randomly chosen pairs represents

a higher state of health. GBD 2013 disability weights were based on the pooled analysis of 60 890 responses from household surveys done in a wide range of settings (USA, Peru, Tanzania, Bangladesh, Indonesia, Italy, Hungary, Sweden, and the Netherlands, and an open access internet survey) to allow them to be generalised to the global population.<sup>22</sup> We analysed the disability weight surveys to generate 235 health state weights on a scale of 0·0 (perfect health) to 1·0 (like death). Each of the 2337 sequelae in the study are mapped to a particular health state and its associated disability weight. Results showed little variation by country of survey or level of education of respondents, justifying the use of a single set of disability weights for all countries and time periods.

YLDs for deprivation areas have been estimated from regional level results. For causes where substantial mortality exists, we have assumed that the pattern of disease prevalence mirrors the pattern of mortality in an age–sex group. For causes where there is minimal mortality and no available data, we have assumed that YLD rates for an age–sex group are constant across deprivation levels in an English region. The threshold used to define minimal mortality is if the ratio of years of life lost (YLLs) to YLDs was less than 0·15.

### Age standardisation, multiple-decrement life tables, and benchmarking years of life lost

The GBD 2013 global age-standard population was used to compute age-standardised rates.<sup>4</sup>

We used multiple-decrement life tables to compute the contribution of changes in cause-specific mortality to changes in life expectancy for each English region and deprivation area from 1990 to 2013.<sup>24,25</sup>

We computed YLLs by multiplying numbers of deaths from each cause in each age group by the reference life expectancy at the average age of death for those who die in the age group, as in the GBD 2010.<sup>9,13,16,26,27</sup> The reference life expectancy at birth is 86·02 years and is based on the lowest age-specific death rates observed in all countries with populations greater than 5 million in 2010. We compared English regions and England as a whole with 18 other comparator nations (the first 15 members of the EU [apart from the UK], Australia, Canada, Norway, and the USA; EU15+). This set of countries has been used in previous benchmarking analyses for the UK.<sup>1</sup>

To describe the proportional share of the variation for deprivation group and English region, ANOVA was carried out at regional level and, for each deprivation area, within English regions. We did the analysis separately for each outcome measure (death, YLLs, YLDs, disability-adjusted

	Death		YLLs		YLDs		DALYs		Life expectancy	
	Deprivation	Region	Deprivation	Region	Deprivation	Region	Deprivation	Region	Deprivation	Region
<b>Men</b>										
1990	86·8% (65·3–96·9)	7·8% (1·2–24·1)	92·5% (78·2–98·5)	5·2% (0·9–17·6)	86·4% (64·6–96·9)	8·5% (1·3–25·9)	96·3% (88·4–99·3)	2·2% (0·3–8·1)	94·2% (82·3–98·8)	4·3% (0·7–13·9)
1995	86·0% (64·6–96·6)	6·0% (0·8–19·5)	93·2% (80·7–98·6)	3·4% (0·5–11·9)	86·3% (66·3–96·6)	7·0% (1·0–20·8)	96·8% (90·7–99·3)	0·9% (0·1–3·7)	93·7% (82·0–98·6)	3·0% (0·4–10·2)
2000	89·7% (73·7–97·6)	4·6% (0·6–14·0)	94·5% (84·3–98·8)	3·2% (0·5–11·3)	89·5% (70·6–97·6)	6·8% (1·1–21·2)	97·7% (92·6–99·5)	0·6% (0·0–3·2)	95·0% (85·3–98·9)	2·4% (0·3–8·3)
2005	92·3% (78·6–98·4)	4·8% (0·7–16·1)	93·7% (81·7–98·6)	4·1% (0·7–13·2)	85·6% (62·9–96·3)	7·6% (1·1–24·9)	96·2% (89·0–99·1)	1·5% (0·1–5·3)	94·6% (83·8–98·9)	3·5% (0·5–11·5)
2010	92·1% (78·2–98·4)	4·5% (0·6–14·9)	92·6% (78·8–98·3)	4·1% (0·6–13·3)	84·0% (59·3–96·0)	9·9% (1·9–29·0)	95·5% (86·7–99·1)	1·2% (0·1–5·6)	94·4% (83·4–98·8)	3·3% (0·5–11·1)
2013	92·8% (80·9–98·5)	3·2% (0·4–10·4)	91·1% (75·1–98·3)	5·1% (0·7–16·0)	86·5% (63·3–97·0)	8·5% (1·4–24·7)	94·3% (84·7–98·8)	2·0% (0·2–7·3)	94·6% (84·5–98·8)	2·5% (0·3–8·6)
<b>Women</b>										
1990	80·1% (54·4–94·6)	9·8% (1·6–31·3)	86·4% (64·1–96·9)	6·8% (1·1–22·8)	86·2% (63·3–96·7)	5·6% (0·8–19·1)	89·2% (73·3–97·5)	4·5% (0·6–15·6)	86·0% (64·3–96·6)	6·7% (1·0–21·4)
1995	82·1% (56·6–95·6)	6·9% (0·9–21·6)	89·6% (70·5–97·4)	5·2% (0·7–17·9)	91·4% (75·2–98·2)	4·6% (0·6–14·8)	93·4% (82·1–98·6)	2·6% (0·3–8·9)	88·2% (68·9–97·2)	4·5% (0·5–15·2)
2000	79·1% (53·1–94·6)	6·2% (0·8–22·8)	85·8% (64·1–96·6)	6·8% (1·1–20·0)	87·4% (67·9–97·2)	4·8% (0·5–17·5)	90·8% (75·8–98·0)	3·2% (0·3–11·9)	85·0% (61·9–96·3)	3·6% (0·2–15·8)
2005	78·3% (48·1–95·3)	13·0% (2·1–35·3)	81·3% (53·3–95·3)	12·5% (2·0–35·5)	81·6% (55·1–95·8)	5·6% (0·6–22·8)	86·6% (66·9–96·9)	6·5% (0·9–20·9)	82·8% (57·4–95·8)	10·5% (1·9–29·3)
2010	80·9% (54·3–95·0)	9·6% (1·5–28·1)	79·1% (50·5–94·4)	12·8% (2·3–36·3)	70·8% (37·7–91·9)	22·1% (4·9–53·5)	85·6% (64·7–96·5)	5·9% (0·9–18·6)	84·5% (61·2–96·2)	7·9% (1·3–24·3)
2013	82·5% (56·0–95·7)	7·8% (1·2–27·4)	78·7% (50·3–94·1)	11·7% (2·3–32·8)	81·4% (57·1–95·5)	7·9% (1·0–26·3)	83·9% (59·8–96·1)	6·4% (0·7–22·7)	86·2% (64·7–96·6)	5·8% (0·8–18·8)

Data are percentage variance (95% uncertainty interval). YLLs=years of life lost. YLDs=years lived with disability. DALYs=disability-adjusted life-years. Deprivation=deprivation area. Region=English region.

**Table 1: Decomposition of variance in deaths, YLLs, YLDs, DALYs, and life expectancy for men and women, separately, into contributions from level of deprivation and English region for 1990, 1995, 2000, 2005, 2010, and 2013**

life years [DALYs], life expectancy), and for specific years (1990, 1995, 2000, 2005, 2010, 2013). Models with main effects for region and deprivation, and of the interaction of English region and deprivation, were fitted to the data. Decomposition of variance was estimated using mixed-effects linear regression employing Gelman's methods.<sup>28</sup> UIs for the decomposition of variance were based on two steps. First, we took 1000 draws from the standard error of the random effect across English regions and the random effect across deprivation levels. Second, we computed the fraction of variance explained by English region and deprivation level based on each of these draws. Table 1 shows the proportion of the variance due to deprivation and due to English region (with 95% UIs).

**Role of the funding source**

The GBD 2013 database development, methods improvement, and global analysis is primarily funded by the Bill & Melinda Gates Foundation, which had no role in study design, data collection, data analysis, data interpretation, or writing of the report. Public Health England contributed to the interpretation of data, the writing of the report, and the decision to submit the paper for publication. The corresponding author had full access to all the data in the study and had final responsibility to submit the paper.

**Results**

Between 1990 and 2013, life expectancy from birth in England increased by 5.4 years (95% UI 5.0–5.8) from 75.9 years (75.9–76.0) to 81.3 years (80.9–81.7), and

age-standardised death rates were reduced by 33.6% (31.1–36.1; appendix p 21). During the same time period, the relative reduction in the rate of age-standardised YLLs was 41.1% (38.3–43.6), indicating a proportionately larger reduction in premature mortality when compared with overall mortality. In comparison, age-standardised rates of YLDs, which capture the burden of disability, decreased by only 1.4% (0.1–2.8). With DALYs, which combine mortality and disability, there was an overall reduction of 23.8% (20.9–27.1) between 1990 and 2013. Compared with the EU15+ countries, in 2013, England ranked eighth for age-standardised death rates, seventh for YLLs, seventh for YLDs, and sixth for DALYs; better than the UK as a whole on all measures. Corresponding results for the constituent countries of the UK and the English regions are provided in the appendix (p 21).

Figure appendix 1 shows the change in life expectancy from 1990 to 2013 by broad cause group for men and women separately and for both sexes combined in England, the English regions, Scotland, Northern Ireland, Wales, and the EU15+ countries. Between 1990 and 2013, England overall achieved one of the largest gains in life expectancy among men, with 6.4 gained years, less than Luxembourg but tying with Finland. All English regions except for South West England, achieved a gain of at least 6.0 years, equal to or greater than all comparator countries except Austria, Finland, Ireland, Germany, and Luxembourg. Among women, the increase in life expectancy in England overall was more modest




Figure 1: The 25 leading GBD level 3 causes of years of life lost (YLLs) in England, both sexes combined, 1990, 2005, and 2013, with age-standardised median percent change. Ranks are based on the number of YLLs. 95% UIs for mean rank are from 1000 draws of YLLs. UI=uncertainty interval. COPD=chronic obstructive pulmonary disease.

	Ischaemic heart disease	Lung cancer	Cerebrovascular disease	COPD	Alzheimer's disease	Lower respiratory infections	Colon and rectum cancers	Breast cancer	Self-harm	Pancreatic cancer	Other cardiovascular	Prostate cancer	Oesophageal cancer	Congenital anomalies	Other neoplasms	Road injury	Preterm birth complications	Cirrhosis hepatitis C	Non-Hodgkin lymphoma	Stomach cancer	Brain cancer	Aortic aneurysm	Ovarian cancer	Leukaemia	Drug use disorders
<b>South East England</b>	897	510	429	299	279	306	289	294	233	154	136	124	126	210	137	177	192	93.2	111	77.3	130	88.5	99.9	106	116
Italy	883	571	487	185	337	100	302	238	201	172	79.6	86.9	37.9	213	172	381	154	115	109	166	114	45.8	71.9	124	54.4
<b>East of England</b>	1007	526	432	279	284	305	292	298	231	151	133	134	120	237	138	197	238	80.1	108	85.1	123	91.6	103	105	117
Sweden	1348	436	500	208	230	164	330	200	492	163	112	182	47.4	195	128	187	57.8	74.6	85	87.4	133	94.2	81.2	110	118
<b>South West England</b>	980	522	466	294	281	298	305	297	281	153	140	132	138	225	140	208	228	103	120	85.5	134	86.6	98.7	114	152
Spain	942	619	489	288	307	210	358	215	232	158	127	100	62.9	215	164	311	93.3	122	85.9	160	123	42.3	68.2	109	113
Australia	994	522	409	276	263	127	312	233	445	154	90.1	149	82.3	230	134	352	109	60.9	118	97.7	129	56.4	67.9	111	171
Norway	1055	582	491	330	355	212	405	194	465	169	105	174	49.3	209	122	215	59.5	53.2	90.3	99.9	143	84.3	91	105	281
Luxembourg	1085	695	592	317	230	184	326	263	432	175	205	111	82.5	109	112	317	64.9	164	101	117	139	38.9	92.1	124	159
<b>Greater London</b>	1103	615	455	375	322	362	277	282	228	155	146	124	116	235	143	152	242	127	120	97.1	118	88	89.1	114	130
<b>England</b>	1122	623	497	367	289	343	305	295	254	154	143	127	138	254	147	193	251	122	113	99.7	125	89.7	100	112	140
<b>East Midlands</b>	1142	598	499	361	290	344	312	302	238	152	141	126	144	265	153	235	285	118	113	102	126	88.6	104	113	116
France	761	785	404	161	178	173	307	278	578	180	181	128	104	197	207	358	67.9	129	103	108	120	40.8	78.6	119	85.3
Canada	1181	760	324	259	346	179	316	243	463	165	83.2	118	65.6	272	139	357	186	91.1	132	91.6	121	55	76.2	116	132
UK	1170	653	520	383	295	348	315	294	280	157	143	128	142	256	149	198	243	129	113	105	127	88.1	101	112	157
Netherlands	1040	861	471	366	272	276	426	337	355	203	176	157	128	256	166	204	102	67.1	104	147	140	83.4	97.9	122	34.5
Germany	1335	632	497	279	289	183	323	256	386	200	183	127	84.4	214	142	241	151	153	86.5	145	132	44.5	82	111	79.6
Austria	1321	592	493	237	287	116	294	240	490	209	115	119	56.5	258	146	293	147	157	106	128	122	43.3	79.9	118	157
<b>West Midlands</b>	1185	611	544	389	291	356	317	300	251	154	135	129	154	333	158	217	335	141	109	114	120	83.9	108	114	124
Ireland	1481	638	504	362	304	337	347	303	460	164	104	155	119	341	122	255	140	65.7	107	124	140	70.1	106	109	158
Finland	1509	450	626	174	446	115	256	204	709	194	114	129	48.6	240	135	238	82.7	198	98.5	113	134	87.6	68	104	212
<b>Yorkshire and the Humber</b>	1314	736	555	442	283	370	315	295	276	155	146	125	139	282	160	212	264	118	111	118	128	87.5	98.2	123	167
Belgium	1112	811	536	391	315	281	314	304	644	177	174	121	99.6	224	145	446	106	120	105	104	132	53	80.4	116	80.1
Wales	1297	667	563	410	359	368	346	315	329	164	161	128	154	254	157	227	246	134	116	120	127	93.7	110	124	204
<b>North East England</b>	1363	886	586	472	295	365	346	303	303	163	149	127	138	229	156	174	196	168	107	133	122	101	99.9	110	192
Denmark	1133	673	625	541	348	260	396	247	404	165	130	150	75.8	235	153	261	180	175	79.3	81	153	95.6	78.8	111	175
Greece	2054	789	962	346	306	197	269	260	133	177	89.2	103	24.4	305	113	622	203	49.9	49.9	160	197	82.7	79.8	147	133
<b>North West England</b>	1351	779	590	479	291	406	328	294	303	156	162	125	170	288	153	203	282	182	110	117	126	95.6	102	111	192
Portugal	868	544	1069	284	295	423	405	240	392	152	111	137	86	213	175	478	83.6	183	102	305	147	31.9	60.2	126	63.9
Northern Ireland	1565	784	622	430	300	432	394	282	385	185	111	147	135	331	159	280	192	129	121	149	138	74.4	114	112	73.9
Scotland	1437	890	686	500	305	356	363	285	481	170	138	131	182	239	157	201	156	192	117	138	146	73.3	103	112	332
USA	1697	782	457	472	422	268	282	238	512	186	136	113	74.7	300	151	615	259	179	121	74.2	114	56	82.6	127	359

**Figure 2: Age-standardised rates of years of life lost (YLLs) for England and the nine English regions relative to EU15 countries, Australia, Canada, Norway, the USA, Scotland, Northern Ireland, and Wales for both sexes combined in 2013**

EU15+ countries, UK constituent countries, and English regions are ordered by the overall mean age-standardised YLL rate. To facilitate comparison, England and the nine English regions are shown in bold. For illustrative purposes only, UK constituent countries and the English regions have been included where they would rank if they were one of the EU15+ countries; this is not to suggest that the health system in a given English region is equivalent to that of any of the countries to which it is adjacent in the list. Rates are colour-coded to denote statistically significant differences from the mean across this set of English regions and countries. Lung cancer=lung, bronchus, and trachea cancer. COPD=chronic obstructive pulmonary disease. Alzheimer's disease=Alzheimer's disease and other dementias. Other cardiovascular=other cardiovascular and circulatory diseases. Cirrhosis hepatitis C=cirrhosis of the liver secondary to hepatitis C. Brain cancer=brain and central nervous system cancer.

than for men, with 4.4 years, yet still equalled or exceeded that of all countries except Finland, Germany, Ireland, Luxembourg, and Portugal.

In 1990, the life expectancy of men in England was lower than in many western countries, such as Canada, France, Norway, the Netherlands, and Spain; however, by 2013, life expectancy of men in England had surpassed that of each of these countries, reaching 79.5 years (95% UI 78.9–80.0). In three regions of England, South West England, East of England, and South East England, the life expectancy of men was 80 years or above, which is better than that in Australia and in Sweden. The main drivers for improvement in life expectancy in nearly all countries and in the English regions have been declines in cardiovascular disease and, to a lesser extent, cancer mortality. Decreases in chronic respiratory disease and road injuries have also been important contributors. Increased mortality from cirrhosis of the liver and from mental and substance use disorders (mostly attributed to alcohol use) made negative

contributions to life expectancy in all the English regions except for Greater London and South East England.

For women, life expectancy at birth across countries and the English regions in 2013 ranged from 81.0 years (95% UI 80.3–81.7) in Scotland to 84.9 years (84.4–85.4) in France. Geographical patterns, however, are somewhat different from those for men, with the highest life expectancy for women in Spain, Italy, and France. Australia and South East England reached a female life expectancy of 84.0 years (83.5–84.5 and 83.3–84.6, respectively) in 2013, whereas two English regions and four countries have a female life expectancy at or below 82 years, namely: North East England, North West England, Scotland, USA, Northern Ireland, and Denmark. As with men, the key drivers of increases in female life expectancy have been reductions in cardiovascular diseases and cancers. For most countries, sex differences in life expectancy decreased between 1990 and 2013; in England, the gap closed by 2.2 years.

	Ischaemic heart disease	Lung cancer	Cerebrovascular disease	COPD	Alzheimer's disease	Lower respiratory infections	Colon and rectum cancers	Breast cancer	Self-harm	Pancreatic cancer	Other cardiovascular	Prostate cancer	Oesophageal cancer	Congenital anomalies	Other neoplasms	Road injury	Preterm birth complications	Cirrhosis hepatitis C	Non-Hodgkin lymphoma	Stomach cancer	Brain cancer	Aortic aneurysm	Ovarian cancer	Leukaemia	Drug use disorders
East of England, deprivation level 5	771	385	355	190	237	247	255	279	182	142	105	127	97.8	177	124	156	194	45.8	101	69	119	70.6	89.4	104	59.6
South East England, deprivation level 5	710	376	396	207	270	287	267	284	194	140	106	122	99.4	177	129	170	148	57.1	107	65.3	133	74.4	90.4	107	56.7
South West England, deprivation level 5	782	389	395	186	257	257	277	280	215	141	113	123	114	178	125	197	155	53	127	78.1	130	75.4	90.2	112	72
East Midlands, deprivation level 5	832	394	394	213	242	272	281	300	190	128	98	118	120	224	144	249	187	66.8	95.3	76.7	144	78.3	87.7	108	50.4
North East England, deprivation level 5	882	454	421	199	196	277	262	289	150	135	103	124	103	269	153	193	168	73.5	101	99.8	130	60.5	81.9	115	72.1
Yorkshire and the Humber, deprivation level 5	919	417	492	228	239	289	275	291	190	136	107	128	117	230	161	219	129	57	106	77	130	70.1	89.3	123	44.5
West Midlands, deprivation level 5	792	363	415	202	228	248	263	307	205	146	99.1	135	114	264	160	217	177	76.7	101	88.1	151	72.1	100	117	85.4
South East England, deprivation level 4	851	459	412	263	265	293	286	297	225	149	137	128	125	181	147	220	167	69.5	106	74.8	140	84.2	102	110	78.1
North West England, deprivation level 5	887	435	465	221	218	319	279	266	204	126	122	124	138	224	158	203	194	75.3	107	81.3	129	76.5	95.4	99.2	73.4
Greater London, deprivation level 5	832	435	394	217	299	340	257	278	195	148	105	126	95	194	163	159	126	57.2	134	75.8	132	77.6	95.5	143	77.6
East of England, deprivation level 4	922	460	430	234	301	298	278	301	181	138	121	141	108	250	134	232	188	55.9	108	74.8	132	90.3	97.9	101	77.8
South West England, deprivation level 4	859	438	457	234	294	293	292	303	246	146	129	137	128	198	130	237	214	71.5	114	79.5	134	73	106	108	77.5
Greater London, deprivation level 4	926	479	416	261	289	352	270	305	154	149	127	122	110	204	128	151	174	77.4	120	83.5	147	88.2	96.6	114	67.1
North East England, deprivation level 4	958	572	480	260	258	306	277	280	194	148	127	120	107	212	170	191	162	88.3	99.3	113	129	89.3	72.7	94.7	112
East Midlands, deprivation level 4	988	472	460	277	253	318	294	304	203	144	129	129	138	260	144	235	196	79.4	112	91.6	122	76.8	112	110	63.6
Yorkshire and the Humber, deprivation level 4	1050	540	495	298	255	319	295	298	217	138	122	120	127	201	166	212	199	67.8	104	102	138	81.9	95.7	106	108
North West England, deprivation level 4	1043	514	525	296	235	351	281	294	233	139	139	119	149	277	128	191	167	87	110	101	129	83.7	95.1	112	80
West Midlands, deprivation level 4	968	451	546	256	289	338	309	299	217	146	117	130	142	206	152	244	244	90.7	107	93.7	121	86.6	103	116	47.8
Greater London, deprivation level 3	1007	531	446	314	311	383	261	291	239	150	131	117	115	220	144	144	222	104	122	94.3	112	76.2	88.1	112	115
South East England, deprivation level 3	982	566	469	332	301	326	296	316	243	165	151	121	144	251	133	175	209	106	116	84.6	127	95.9	107	109	104
Greater London, deprivation level 3	1000	503	473	292	273	299	302	305	302	152	139	133	139	264	160	221	248	102	127	81.6	133	96	107	115	127
East of England, deprivation level 3	1066	567	465	300	311	326	313	298	229	162	150	137	129	254	147	212	241	89.2	105	98.2	126	98.6	125	112	118
<b>England</b>	1122	623	497	367	289	343	305	295	254	154	143	127	138	254	147	193	251	122	113	99.7	125	89.7	100	112	140
North East England, deprivation level 3	1260	742	488	362	265	339	317	280	277	131	140	113	135	274	136	141	107	132	105	118	117	92.9	119	103	90.8
East Midlands, deprivation level 3	1158	604	551	359	313	372	306	309	240	161	144	127	151	260	158	274	287	105	122	106	118	91.2	106	127	103
Greater London, deprivation level 2	1189	687	467	434	331	367	279	279	255	152	156	124	117	236	146	163	255	150	120	101	116	91.1	93.5	119	134
Yorkshire and the Humber, deprivation level 3	1230	629	563	371	281	353	321	305	272	147	141	123	128	260	169	217	262	94.2	96.9	117	154	81.4	94.2	140	103
West Midlands, deprivation level 3	1127	561	566	342	323	369	311	294	248	146	141	131	147	329	173	244	275	115	107	110	133	83.2	116	127	134
South West England, deprivation level 2	1165	665	507	392	294	322	331	297	288	162	165	131	162	222	140	207	249	142	113	89.6	140	99	87.3	133	214
South East England, deprivation level 2	1159	725	465	452	300	340	328	286	256	175	175	127	158	249	155	146	257	149	118	100	122	106	103	104	204
North West England, deprivation level 3	1189	643	579	361	286	397	335	281	266	156	150	128	152	280	163	200	223	131	103	108	144	91.8	103	138	121
East of England, deprivation level 2	1279	712	500	412	294	367	346	331	303	158	158	128	154	235	157	201	327	122	114	104	114	113	109	106	174
Greater London, deprivation level 1	1377	812	525	553	365	377	308	263	240	173	182	130	133	267	147	150	295	181	119	118	100	102	76.8	105	180
West Midlands, deprivation level 2	1334	748	567	481	293	406	352	305	275	157	146	134	169	317	175	224	367	166	119	125	105	84.9	117	121	129
East Midlands, deprivation level 2	1368	781	560	474	332	387	349	298	263	162	158	126	157	274	162	200	360	155	118	125	121	96.9	116	125	139
Yorkshire and the Humber, deprivation level 2	1433	874	589	526	303	407	304	287	290	167	161	134	162	259	163	204	267	134	117	129	120	98.2	113	137	184
North East England, deprivation level 2	1477	982	677	548	311	392	396	315	328	175	159	140	150	187	189	205	205	167	114	137	120	110	104	121	181
North West England, deprivation level 2	1520	850	647	569	364	439	335	313	330	166	174	128	191	253	158	224	327	188	120	124	108	112	103	105	202
South East England, deprivation level 1	1449	961	516	623	286	362	337	291	362	179	196	127	183	242	140	190	241	234	136	91.4	111	139	128	105	314
East of England, deprivation level 1	1658	916	521	517	296	384	321	306	402	197	193	133	164	334	146	192	286	201	145	115	114	125	101	100	301
West Midlands, deprivation level 1	1634	917	610	653	305	415	355	307	275	179	164	118	193	408	148	193	418	232	117	150	109	91	107	103	171
East Midlands, deprivation level 1	1653	961	600	644	346	429	368	307	304	185	211	132	169	307	168	229	366	231	126	131	125	115	102	102	230
South West England, deprivation level 1	1481	961	583	616	309	392	386	303	438	198	205	141	183	279	147	137	294	246	128	138	130	107	99.3	92.6	407
Yorkshire and the Humber, deprivation level 1	1854	1171	638	761	333	473	375	299	346	185	189	122	160	359	150	220	335	204	129	156	113	103	99.4	115	280
North East England, deprivation level 1	1818	1318	723	753	372	443	408	324	399	198	182	131	169	236	141	154	237	275	112	170	119	129	110	114	315
North West England, deprivation level 1	1888	1264	696	822	340	500	390	312	377	181	204	128	206	331	161	199	342	324	115	154	124	111	111	112	314

**Figure 3: Age-standardised rates of years of life lost (YLLs) for England relative to the deprivation levels in the nine English regions for both sexes combined in 2013**  
 To facilitate comparison, England is shown in bold. Lung cancer=lung, bronchus, and trachea cancer. COPD=chronic obstructive pulmonary disease. Alzheimer's disease=Alzheimer's disease and other dementias. Other cardiovascular=other cardiovascular and circulatory diseases. Cirrhosis hepatitis C=cirrhosis of the liver secondary to hepatitis C. Brain cancer=brain and central nervous system cancer.

Figure appendix 2 shows a similar analysis of changes in life expectancy from 1990 to 2013 by cause for the 45 deprivation areas of England. For men, life expectancy in 2013 ranged from 74.9 years (95% UI 74.1–75.7) in North West England deprivation level 1 (most deprived) to 83.1 years (82.3–83.9) in East of England deprivation level 5 (least deprived; figure appendix 2). The range of 8.2 years between deprivation areas in 2013 is unchanged for men since 1990. For women, the equivalent figures in 2013 were 79.5 years (78.7–80.2) in North West England deprivation level 1 (most deprived) to 86.4 years (85.6–87.3) in East of England deprivation level 5 (least

deprived; figure appendix 2); the range has therefore decreased for women from 7.2 years to 6.9 years. Overall, there has been little if any improvement in inequality in life expectancy across regions of England: by 2013, people living in the most deprived areas have not yet reached the levels of life expectancy that less deprived groups had in 1990.

The ordering of the 45 deprivation areas largely follows deprivation level across English regions. There are a few crossovers

Mean rank (95% UI)	1990 leading causes	2005 leading causes	Mean rank (95% UI)	Age-standardised median percentage change 1990-2005	2013 leading causes	Mean rank (95% UI)	Age-standardised median percentage change 2005-2013
1.0 (1-1)	1 Ischaemic heart disease	1 Ischaemic heart disease	1.2 (1-2)	-45% (-46 to -37%)	1 Low back and neck pain	1.1 (1-2)	10% (3 to 15%)
2.1 (2-3)	2 Low back and neck pain	2 Low back and neck pain	1.8 (1-2)	8% (3 to 14%)	2 Ischaemic heart disease	1.9 (1-2)	-20% (-24 to -15%)
2.9 (2-3)	3 Cerebrovascular disease	3 Cerebrovascular disease	3.1 (3-4)	-27% (-30 to -20%)	3 Cerebrovascular disease	3.9 (3-6)	-12% (-17 to -7%)
4.0 (4-4)	4 Lung cancer	4 COPD	4.5 (3-7)	-5% (-9 to 3%)	4 COPD	4.3 (3-7)	1% (-5 to 8%)
5.1 (5-6)	5 COPD	5 Lung cancer	4.9 (4-8)	-21% (-25 to -19%)	5 Lung cancer	4.9 (3-8)	0% (-7 to 7%)
6.6 (6-8)	6 Falls	6 Falls	6.8 (5-9)	3% (-5 to 7%)	6 Alzheimer's disease	6.7 (5-10)	11% (2 to 20%)
8.7 (6-11)	7 Lower respiratory infections	7 Alzheimer's disease	7.6 (6-10)	19% (9 to 30%)	7 Sense organ diseases	6.8 (3-11)	9% (5 to 12%)
8.9 (6-14)	8 Sense organ diseases	8 Sense organ diseases	8.1 (4-11)	7% (4 to 11%)	8 Depressive disorders	8.8 (3-14)	9% (4 to 12%)
9.5 (7-12)	9 Alzheimer's disease	9 Skin diseases	9.3 (4-14)	5% (1 to 9%)	9 Falls	9.0 (7-11)	-11% (-17 to -4%)
9.7 (5-17)	10 Depressive disorders	10 Depressive disorders	9.8 (4-15)	1% (-5 to 8%)	10 Skin diseases	9.3 (4-14)	2% (-1 to 5%)
9.9 (6-16)	11 Skin diseases	11 Lower respiratory infections	10.2 (7-13)	-1% (-19 to 3%)	11 Diabetes	10.6 (8-13)	16% (7 to 27%)
12.1 (9-14)	12 Colorectal cancer	12 Diabetes	12.4 (10-16)	25% (13 to 38%)	12 Lower respiratory infections	12.5 (8-16)	-15% (-20 to -6%)
12.1 (9-16)	13 Breast cancer	13 Breast cancer	14.6 (11-18)	-15% (-19 to -12%)	13 Chronic kidney disease	14.0 (10-19)	8% (4 to 10%)
14.2 (12-17)	14 Road injuries	14 Chronic kidney disease	15.1 (11-19)	2% (-2 to 7%)	14 Colorectal cancer	15.1 (12-18)	0% (-6 to 6%)
16.1 (12-20)	15 Chronic kidney disease	15 Colorectal cancer	15.4 (12-19)	-16% (-20 to -15%)	15 Migraine	15.5 (10-22)	0% (-8 to 11%)
17.0 (14-20)	16 Diabetes	16 Migraine	15.5 (10-23)	9% (0 to 22%)	16 Other musculoskeletal	16.4 (12-21)	10% (6 to 13%)
17.6 (15-20)	17 Congenital anomalies	17 Other cardiovascular	16.8 (14-21)	32% (-11 to 64%)	17 Anxiety disorders	16.8 (10-28)	5% (4 to 8%)
17.7 (10-25)	18 Migraine	18 Anxiety disorders	17.7 (10-28)	6% (2 to 9%)	18 Breast cancer	17.0 (13-21)	-11% (-17 to 0%)
18.8 (15-22)	19 Self-harm	19 Other musculoskeletal	18.1 (13-23)	16% (12 to 20%)	19 Other cardiovascular	18.2 (15-22)	-8% (-25 to 9%)
19.2 (10-30)	20 Anxiety disorders	20 Drug use disorders	20.3 (18-24)	27% (1 to 39%)	20 Drug use disorders	20.2 (18-23)	0% (-6 to 5%)
21.4 (16-26)	21 Other musculoskeletal	21 Road injuries	21.0 (18-23)	-33% (-35 to -31%)	21 Congenital anomalies	20.5 (17-23)	2% (-7 to 13%)
22.1 (18-25)	22 Other cardiovascular	22 Congenital anomalies	21.0 (18-23)	-19% (-24 to -15%)	22 Oral disorders	20.8 (14-27)	11% (8 to 15%)
22.4 (20-25)	23 Neonatal preterm birth	23 Oral disorders	23.0 (16-29)	-1% (-5 to 2%)	23 Neonatal preterm birth	24.7 (22-30)	-3% (-16 to 14%)
23.4 (17-29)	24 Oral disorders	24 Self-harm	23.7 (19-27)	-28% (-30 to -15%)	24 Self-harm	25.5 (22-30)	-12% (-23 to -3%)
25.0 (21-29)	25 Drug use disorders	25 Neonatal preterm birth	25.2 (23-28)	-16% (-28 to -5%)	25 Iron-deficiency anaemia	25.5 (21-33)	3% (-3 to 5%)
		26 Iron-deficiency anaemia			29 Road injuries		

Figure 4: The 25 leading GBD level 3 causes of disability-adjusted life years (DALYs) in England, both sexes combined, 1990, 2005, and 2013, with age-standardised median percent change. Ranks are based on the number of DALYs. 95% UIs for mean rank are from 1000 draws of DALYs. UI=uncertainty interval. COPD=chronic obstructive pulmonary disease.

presents the results of the ANOVA analysis by year for various measures in this group. For men in 2013, at least 85% of variation was associated with IMD-2010 score, and less than 10% was associated with English region for all measures, whereas for women the values explained by level of deprivation of the area were slightly lower, especially for mortality.

Change across all deprivation areas was dominated by decreases in cardiovascular diseases and cancers. Increased death rates from cirrhosis of the liver, mental and substance use disorders, and neurological diseases, which were largest in the most deprived areas, reduced the progress that would otherwise have been achieved from reductions in other causes.

Figure 1 shows the leading causes of YLLs using broad disease categories (level 3 in the GBD cause hierarchy). The leading causes of death overall are shown in the appendix (p 1). Ranking is based on the number of YLLs from each cause, which is a function of age-specific rates and the distribution of the population by age and sex in 1990 and 2013. Changes in the number of YLLs and the age-standardised YLL rate are shown to highlight the effect of demographic change on numbers of YLLs (eg, YLLs due to Alzheimer's disease and other dementias have increased by 31% despite a 3% decline in the age-standardised rate). The top four causes of death in 1990 (ischaemic heart disease, cerebrovascular disease, lung cancer, and chronic obstructive pulmonary disease [COPD]) remain at the top in 2013, despite substantial

declines in their age-standardised rates. Lung cancer and cerebrovascular disease switched ranks because of the large change in cerebrovascular disease age-standardised rates (-55%, 95% UI -59 to -50) between 1990 and 2013. Alzheimer's disease and other dementias increased in rank (from eighth to fifth) even though there was a statistically non-significant decline in age-standardised rates; this needs to be considered in view of an increase in the recording of Alzheimer's disease on death certificates.<sup>29</sup> Lower respiratory infections, colorectal cancer, breast cancer, and self-harm all remained highly ranked but still showed reductions in age-standardised YLL rates of more than 34% and a reduction in numbers of YLLs. Large reductions in both numbers and rates of YLLs were also observed for preterm birth, road injuries, aortic aneurysm, and diabetes. By contrast, as for Alzheimer's disease and other dementias, YLL numbers for several other cancer types increased even though age-standardised rates declined slightly. There were increases in both numbers and rates for only a small number of causes, notably cirrhosis of the liver due to hepatitis C and drug use disorders.

Figure 2 shows age-standardised YLL rates for both sexes from GBD level 3 causes in England and its nine regions relative to the EU15+ countries. Across the EU15+ countries, the absolute and relative ranges in age-standardised rates for different causes are markedly different. Within the EU15+ countries, the ratio of maximum rate to minimum rate is less than 2.0 for eight

	Deaths	YLLs	YLDs	DALYs	Total burden of DALYs 2013
Cerebrovascular disease	-46.2% (-50.65 to -37.93)*	-54.9% (-59.01 to -49.67)*	14.2% (7.89 to 20.12)*	-49.8% (-54.40 to -44.69)*	535 900 (475 100 to 607 000)
Chronic obstructive pulmonary disease	-19.3% (-27.43 to -2.76)*	-32.4% (-39.25 to -21.41)*	-0.9% (-12.25 to 10.28)	-21.9% (-28.42 to -15.25)*	527 200 (448 800 to 620 400)
Alzheimer's disease and other dementias	6.9% (-6.42 to 20.11)	-3.4% (-14.31 to 6.87)	0.2% (-11.40 to 10.40)	-2.2% (-11.61 to 5.78)	463 400 (412 800 to 514 600)
Diabetes	-50.4% (-53.89 to -46.91)*	-55.8% (-58.66 to -52.73)*	75.3% (56.88 to 94.11)*	20.1% (5.51 to 34.98)*	360 200 (262 900 to 468 900)
Prostate cancer†	-16.2% (-44.83 to 0.52)	-20.9% (-51.37 to -6.46)*	42.6% (2.52 to 72.19)*	-14.2% (-45.70 to 1.21)	138 100 (93 300 to 186 200)
Liver cancer	56.6% (11.83 to 87.65)*	41.0% (6.19 to 66.01)*	72.3% (18.86 to 126.55)*	41.4% (6.34 to 66.45)*	49 400 (37 500 to 57 200)
Cirrhosis of the liver	41.7% (31.71 to 51.08)*	50.8% (40.64 to 61.31)*	26.2% (20.17 to 32.34)*	50.0% (40.15 to 60.25)*	181 000 (169 000 to 192 500)
Drug use disorders	113.5% (6.99 to 143.31)*	107.7% (4.07 to 137.47)*	-4.9% (-9.68 to 0.19)	18.2% (-1.56 to 28.47)	201 200 (157 300 to 246 500)

Data are percent change (95% UI). YLLs=years of life lost. YLDs=years lived with disability. DALYs=disability-adjusted life-years. \*Statistically significant. †Men only.

**Table 2: Change in age-standardised rates (per 100 000) of death, YLLs, YLDs, and DALYs for both sexes from 1990 to 2013 for select disorders in England and total DALYs in 2013**

of the top 25 causes: leukaemia, ovarian cancer, brain cancer, other neoplasms, pancreatic cancer, breast cancer, colorectal cancer, and lung cancer. Ratios of maximum-to-minimum rate greater than 4.0 are seen for drug use disorders (10.4), oesophageal cancer (5.8), lower respiratory infections (4.2), neonatal preterm birth (4.5), self-harm (5.3), and stomach cancer (4.1). Across English regions, the only cause with a ratio of maximum-to-minimum rate greater than 2.0 is cirrhosis of the liver due to hepatitis C (2.3). Eight other disorders have a ratio between 1.5 and 2.0: ischaemic heart disease, lung cancer, COPD, congenital abnormalities, road injuries, neonatal preterm birth, stomach cancer, and drug use disorders. For some causes, such as lower respiratory infections and breast cancer, all English regions are significantly above the international mean, indicating that England is performing poorly for these disorders. For self-harm and road injuries, the opposite is true with all English regions being significantly below the mean.

Figure 3 is a comparison of age-standardised YLL rates for causes within each deprivation area with the England rate in 2013. Some causes such as ischaemic heart disease or COPD are largely ordered following the overall age-standardised YLL rate, whereas other causes have distinct patterns. Breast cancer and prostate cancer show much less variation across the deprivation areas. Other neoplasms and road injuries have variable patterns: in some regions, deprivation level 5 (least deprived) has higher rates than deprivation level 1 (most deprived) in other regions. Lymphoma, leukaemia, and brain cancer have distinctive patterns that do not follow levels of deprivation. The ratio of maximum age-standardised YLL rate to minimum age-standardised YLL rate across deprivation areas as a measure of relative inequality ranges from 1.3 (low) for prostate cancer to 9.2 (high) for drug use disorders. Other examples of high ratios include COPD (4.4), and cirrhosis from hepatitis C (7.1). In 2013, 91.1% of the variance in YLLs for men is explained by deprivation area and only 5.1% by region (table 1); for women, 78.7% of the variance is explained by deprivation area and 11.7% by region (table 1).

Levels of YLDs from 1990 to 2013 have changed much less than YLLs for England (appendix p 21). Figure 4 provides the overall assessment of trends in DALYs using level 3 of the GBD cause hierarchy from 1990 to 2013. The leading cause of DALYs in 2013 is low back and neck pain. Sense organ diseases, consisting of hearing loss and vision loss, and depressive disorders are leading causes of DALYs although they do not cause substantial YLLs. Other causes such as chronic kidney disease, migraine, and eating disorders are important causes of YLDs and DALYs. Other musculoskeletal disorders, anxiety disorders, and drug use disorders are also leading causes of DALYs. Age-standardised DALY rates by deprivation areas for the leading causes of DALYs are provided in the appendix (p 2). Some causes, such as depressive disorders, show substantial variation among deprivation areas across English regions. For many causes that predominantly lead to YLDs, UIs are large such that nearly all deprivation areas have levels that are not significantly different from the England mean.

DALY trends are a composite of trends in YLLs and YLDs; trends that in some cases, might be going in opposite directions. Examples of disorders for which YLL and YLD rates are changing in different directions, or where all measures are increasing markedly, can be seen in table 2. For instance, age-standardised YLL rates for prostate cancer significantly declined by 20.9% (95% UI 6.46–31.37), whereas YLD rates significantly increased by 42.6% (2.52–72.19). Such examples show that only summary measures combining morbidity, mortality, and disability data provide a comprehensive understanding of the effect of a disorder on a population.

Estimates for deaths, YLLs, YLD, and DALYs in England in 1990 and 2013 for all ages and age-standardised rates are provided in the appendix (pp 23–40).

Overall for England in 2013, all identified risk factors jointly explain 39.6% (95% UI 37.7–41.7) of DALYs, with the remaining 60.4% DALYs as yet unexplained by the risk factors analysed (figure 5). Risk factors together explain 83.9% (81.6–86.2) of cardiovascular disease DALYs, 46.7% (44.5–49.3) of neoplasm DALYs, 49.7%




Figure 5: Proportion of all-cause DALYs (A), cardiovascular disease DALYs (B), neoplasm DALYs (C), and injury DALYs (D) attributable to behavioural, environmental and occupational, and metabolic risk factors and their overlaps for all ages in 2013




Figure 6: Disability-adjusted life-years (DALYs) attributed to level 2 risk factors in 2013 in England for both sexes combined (A), men (B), and women (C)

(46.5–52.6) of injury DALYs, 62.0% (57.9–65.9) of chronic respiratory disease DALYs, but only 1.9% (1.4–2.4) of neurological disease DALYs (figure 5; DALYs attributable to risk factors for chronic respiratory disease and neurological disease are not presented; for DALYs attributable to all risk factors, see appendix p 41).

Behavioural risks account for 28.0% (95% UI 25.6–30.3) of DALYs, metabolic risks for 19.2% (18.0–20.5), and environmental and occupational risks for 4.7% (4.3–5.2). Almost half of DALYs due to metabolic risks overlap with behavioural risks, which is particularly large for cardiovascular disease. Behavioural risks (particularly tobacco and dietary risks) are the greatest contributor to cancer with more modest contributions from metabolic risks and environmental and occupational risks. Low bone mineral density and alcohol consumption are the dominant metabolic and behavioural risks, respectively, for injuries (figure 5).

The largest contributor to DALYs are dietary risks (10.8%, 95% UI 9.1–12.7), an aggregate in the second tier of the GBD risk hierarchy of low fruit consumption, low vegetables consumption, low whole-grains consumption, low nuts and seeds consumption, low milk consumption, high red meat consumption, high processed meat consumption, high sugar-sweetened beverages consumption, low fibre consumption, suboptimal calcium intake, low seafood omega-3 fatty acids consumption, low polyunsaturated fatty acids consumptions, high trans fats intake, and high sodium intake, closely followed by tobacco (10.7%, 9.4–12.0) (figure 6).

The rates of DALYs attributed to each of the three major risk categories have declined between 1990 and 2013: by 28.3% (95% UI 25.0–31.5) for metabolic risks, by 23.7% (21.5–26.0) for behavioural risks, and by 28.8% (23.7–35.0) for environmental and occupational risks (data not shown). Declines are due to reductions in DALY rates attributable to most risk factors: between 1990 and 2013, DALY rates significantly declined for 11 of the 15 largest risks at tier 3 in the risk hierarchy (tobacco, high blood pressure, cholesterol, low glomerular filtration rate, low physical activity, diet low in fruit, vegetables, nuts, and seeds, diet high in sodium and processed meat, and air pollution), but remained unchanged for high body-mass index (BMI), high fasting plasma glucose, and alcohol. Illicit drug use is the only top 15 risk for which the DALY rates increased significantly. These changes in DALY rates attributed to major risks can be caused by a change in risk exposure, a change in outcomes associated with the risk, or a combination of the two. There was a significant decline in exposure to tobacco, high blood pressure, cholesterol, and air pollution. Exposure to the top dietary risks, physical activity, alcohol use, and low glomerular filtration rate changed little. Exposure to high BMI and high fasting plasma glucose increased significantly, but large declines in cardiovascular disease outcomes are mainly responsible for the difference in trends between exposure and attributable burden. Of the

ten leading tier 2 risks, seven cause a greater proportion of total DALYs in men than in women. The exceptions are physical inactivity, fasting plasma glucose, and low glomerular filtration rate, with equal proportions of DALYs between men and women (figure 6).

The leading risk factors by deprivation level in England are shown in the appendix (p 3). There is a consistency of rank order of major risk factors: smoking, high BMI, and high blood pressure are the leading risks in all deprivation areas. Smoking is strongly socially stratified: it ranks above high BMI in deprivation level 1 (most deprived) in all English regions, but the converse is true in deprivation levels 4 and 5 across seven of those nine regions. In deprivation level 1 in six regions, alcohol use is the fourth leading risk factor, whereas it is high fasting plasma glucose for other regions. Drug use is a more highly ranked risk factor in most of the more deprived areas when compared with less deprived areas.

## Discussion

England had better than average outcomes in 2013 when compared with EU15+ countries and other countries of the UK. Despite sharing the same health and social care system, some English regions have outcomes commensurate with, or better than, those of the best-performing nations among the EU15+ countries, whereas others have outcomes worse than any of these countries. Life expectancy has increased at all levels of deprivation within English regions, but the variation in life expectancy within regions has decreased only slightly for women and not at all for men.

Routine annual mortality statistics show a year-on-year decline in age-standardised mortality rates in England and the rest of the UK from 1983 to 2013:<sup>30</sup> mortality rates in Scotland are known to have been higher than in England, whereas mortality rates in Wales and Northern Ireland, although higher, have generally been closer to those in England. Routine statistics show that the range in life expectancy at birth between regions has reduced for men in the past 5 years, from 2.7 years to 2.4 years, but stayed the same for women, at 2.4 years.<sup>31</sup> Our results show a larger range in life expectancy between deprivation areas, at 8.2 years for men and 6.9 years for women in 2013, with only a small reduction since 1990 for women and none for men. Routine mortality statistics undifferentiated by deprivation thus mask substantial inequalities within English regions (figure appendix 2). Consistent with other analyses,<sup>32–35</sup> geography accounted for only a small proportion of the variance between deprivation areas (table 1). At the district level, populations are more homogeneous, and inequalities in mortality rates more evident. District-level data reported by Bennett and colleagues<sup>36</sup> suggest inequalities at this level are increasing. Inequality within regions is therefore greater than it is between them, and it is therefore important to address the problems caused by deprivation wherever they occur and in all regions of the country.

Many of the most common causes of DALYs show striking variation by deprivation area (appendix p 2); as for mortality, this inequality largely follows patterns determined by level of deprivation, not geography. For low-mortality disorders, such as musculoskeletal disease, DALYs tend to be based on incomplete data at subnational level, and the level of inequality for many disorders is likely to be underestimated.

The Greater London deprivation groups are an exception to the overall pattern of inequality because their burden of disease is less than expected for their level of deprivation (see figure appendix 2 and appendix p 2). Possible explanations include artifact due to the method of measuring deprivation, ethnic composition of the population, healthy migrant effect, and differential selective migration within England.<sup>37</sup> London has also received more health investment than other English regions. The effect of health-care spending on the outputs from GBD would be a useful next stage of analysis.

Improvements in life expectancy in England, as elsewhere, have been driven by decreases in mortality from cardiovascular disease and cancers.<sup>38</sup> Increasing mortality from neurological disorders and cirrhosis of the liver have partially offset these gains. In other countries, the negative effect of liver disease has been much less marked (see France, Spain, Sweden, and Italy in figure appendix 2). This rising burden of liver disease in England requires both a policy and health-care response.<sup>39</sup> Among the other leading causes of premature death, Alzheimer's disease and other dementias are increasingly important, although age-specific death rates have declined slightly, consistent with a decline observed in serial prevalence surveys.<sup>21,40-42</sup>

Significant differences in YLL rates by country for specific causes (figure 2) include various cancers. International and subnational differences in mortality are likely to be strongly driven by differences in incidence as well as in survival (eg, for lung cancer). Any national strategy for cancer needs to address primary prevention as well as effective care for people with cancer.

Musculoskeletal disorders are a dominant cause of YLDs, and consume a substantial amount of health-system resources. These disorders are strongly age-related and will become increasingly prevalent as the population ages.<sup>43</sup> Another major contributor to YLDs are depressive and anxiety disorders, the rates of which have not declined. Given the epidemiological assessment of relative burden, services for these disorders rarely receive the attention they deserve. This relative neglect is beginning to change with calls for parity of esteem for mental and physical health. Opportunities to improve management of anxiety and depression in primary care exist;<sup>44-46</sup> evidence suggests that prevention aimed at high-risk groups before depression arises is effective.<sup>47</sup>

For several disorders, although mortality rates may have reduced, the burden of ill health has either not declined by the same extent or is increasing. In England, and in other

high-income countries, a larger share of DALYs now comes from YLDs, rather than YLLs. For example, in cerebrovascular disease and diabetes, YLLs have decreased, but YLDs have increased significantly; for COPD, YLLs have decreased significantly but with almost no change in YLDs. Whereas mortality rates from cardiovascular complications of diabetes have fallen, the prevalence of people living with diabetes is rising. Data from the National Diabetes Audit show that 36·0% of people with diagnosed diabetes living in England are estimated to have had their HbA<sub>1c</sub>, blood pressure, and cholesterol values treated to target in 2012-13.<sup>48</sup> These data together indicate a high level of unmet need for prevention of the consequences of diabetes and for the active management of long-term disorders in general.

In some cases, the increasing relative contribution of YLDs might be the effect of improved survival (eg, from stroke and some cancers), leading to higher prevalence and many people living with disorders that previously would have proved fatal. Survivors will also be at risk of developing other disorders, particularly disorders associated with ageing, leading to steadily increasing lifetime risks of some cancers and of musculoskeletal disease, for example. One consequence of the growing phenomenon of survivorship, together with the effect of population ageing, will be much higher numbers of patients with multimorbidity than in the past.

A major strength of the GBD study is the ability to estimate the contribution of different causal factors to the burden of mortality and morbidity and, by implication, the extent to which that burden could be reduced by modifying those risks. GBD 2013 was developed to increase understanding of the individual and overlapping effects of different risk factors, generating outputs that are more informative to formulate preventive strategies. The overall proportion of preventable burden reduced between 1990 and 2013 because of the decline in the incidence of the more preventable diseases (ischaemic heart disease and some cancers) and a relative increase in other diseases with an apparently lower potential for prevention (neurological disorders, and Alzheimer's disease and other dementias).

Important metabolic risks, including high blood pressure, high fasting plasma glucose, low glomerular filtration rate, and high cholesterol, overlap significantly with modifiable behavioural risk factors, such as diet and physical activity; for example, mean systolic blood pressure in the UK has fallen by over 3 mm Hg in the last decade, mainly as a result of reduced dietary salt intake.<sup>49,50</sup> In general, behavioural risk factors make a greater contribution to DALYs (28%) than metabolic risks (19%) or environmental and occupational risks (5%). The relative contribution of individual risks and type of risk will vary by disorder. Environmental risks, such as air pollution, albeit smaller than the other two risk categories, remain quantitatively important and require specific consideration within national and local public health policy and strategy.

The combination of unhealthy diets, physical inactivity, and high BMI is the biggest overall contributor to DALYs. Tobacco smoking remains a leading attributable risk factor for DALYs in England, and is notably still the leading risk factor for women. In line with this, mortality from lung cancer for men declined by 24% between 1990 and 2013 but did not change significantly for women. The peak effect of smoking in women is probably only now being reached in England.<sup>38</sup>

Alcohol consumption is the third leading behavioural risk factor overall but is the leading behavioural cause of injury. In GBD 2013, only about a third of deaths from cirrhosis could categorically be assigned to alcohol as the underlying cause (cirrhosis due to alcohol accounts for only 29.4% of DALYs due to cirrhosis; appendix p 36); however, alcohol also contributes to cirrhosis where it is not the underlying cause. In the risk factor analysis, therefore, the proportion of cirrhosis of the liver DALYs attributed to alcohol in England was 69.5% in 2013. This estimate is comparable to findings of another study<sup>39</sup> that showed 75% of cirrhosis of the liver to be attributable to alcohol. Improved data on cirrhosis of the liver and liver cancer by aetiology are needed, including a better assessment of the role of obesity as a cause of fatty liver disease.<sup>51–55</sup> The contributions of various aetiologies to cirrhosis of the liver will probably vary geographically across England.

Most, if not all, behavioural, metabolic, and environmental and occupational risks are strongly related to the socioeconomic determinants of health, which need to be addressed in any credible public health strategy.<sup>56</sup> In future rounds of the GBD study, we plan to quantify socioeconomic determinants of health more directly.

This study has several important limitations beyond those applying more generally to GBD studies and reported elsewhere.

First, the level of aggregation of causes affects their relative ranking (eg, splitting cirrhosis of the liver by cause affects where the individual causes appear in the rankings). The online data visualisations associated with this study allow the user to interrogate the results using different levels of the GBD cause hierarchy.

Second, subnational data at the regional level are not available for the estimation of prevalence and incidence for several diseases. Estimates depend on the GBD Bayesian models, borrowing from studies in other settings while using covariates as predictors. This limitation could be improved by collecting additional data on morbidity in the English population. Possible approaches include increasing the sample size of the Health Survey for England and augmenting the increased sample size with additional health examinations, incorporating data from large primary care surveys, such as the Clinical Practice Research Datalink, or further use of linked primary and secondary care datasets. These estimates might be affected by supply and access factors.

Third, we assigned each lower super output area on the basis of the level of deprivation in 2010 and used this assignment for the analysis in all time periods. As some of the lower super output areas may have changed their relative level of deprivation during the period, we might have underestimated some of the inequalities related to deprivation in 1990. Any reductions in inequality would probably be underestimated because of this approach. Such errors could be assessed by reference to longitudinal studies such as the ONS Longitudinal Study. Furthermore, deprivation is measured at the time that disease outcome is recorded, whereas the contribution of deprivation is relevant across the lifecourse. The estimation of the relation between deprivation and disease does not account for this, thereby potentially underestimating its effect in some areas and overestimating it in others.

Fourth, in view of the limited data by deprivation level for some causes that do not affect mortality, inequality across deprivation levels might be substantially underestimated in the analysis of YLDs.

Fifth, the current GBD method for risk factor attribution uses data on exposure to single risk factors and its effect on each outcome, whereas aggregated effects of risk factors are made on the basis of assumptions of additive, multiplicative, or mediated effects and not on the direct measurement of exposure to combined risk factors and the combined effect on outcomes.

Finally, in some analyses, comparisons are made between English regions and other countries. Although some English regions are similar in size to several of the countries in the EU, the potential for differential migration between English regions is greater than between countries; such comparisons are not straightforward.

Some limitations are specific to certain disorders. The comparative risk assessment, based on the criterion of convincing or probable evidence, did not identify any modifiable risk factors for Alzheimer's disease and other dementias as suitable targets for public health action. Some studies suggest that modifiable behavioural risks do exist,<sup>57–62</sup> but more research is needed to determine whether these findings would meet the criterion for inclusion in the GBD framework. In future rounds of GBD, we intend to make separate estimates for Alzheimer's disease and vascular dementia and will assess the evidence for the effect of some metabolic and behavioural risk factors on vascular dementia in particular. In the GBD 2013 framework, dementia in Parkinson's disease or in stroke is considered in the respective disease categories rather than in the Alzheimer's and other dementias category.

We estimate that about 3600 deaths were attributable to self-harm in England in 2013. This differs from official figures released by the Office for National Statistics, which indicate 4722 suicides in England in 2013.<sup>63</sup> This difference is due to the partial redistribution in the GBD study of ICD-10 mortality codes for injury and poisoning of undetermined intent (ICD-10 codes Y10–Y34) to

For the ONS Longitudinal Study see <http://www.ons.gov.uk/ons/guide-method/user-guidance/longitudinal-study/index.html>

For the IHME online data visualisations see <http://vizhub.healthdata.org/gbd-compare/england>

For NICE's 2013 guide to technology appraisal see <http://www.nice.org.uk/article/pmg9/chapter/foreword>

suicide as opposed to all these codes being counted as suicide by the Office for National Statistics; our estimates will therefore underestimate the overall suicide burden in England compared with official figures. Furthermore, when we estimated the attributable risk for mental and substance use disorders and self-harm, social risk factors (for example, divorce, low income, debt and job loss) were not included and therefore not attributed.

The contribution of diet components other than sugar-sweetened beverages to BMI has not been included in this analysis; therefore, the full consequences of diet might be greater than the effect shown in these results.

No comprehensive picture has been made of the level and distribution of the burden of disease in England, despite the fact that health policy is now devolved to individual countries within the UK. The outputs of such a framework can help test whether the effort being expended on a particular disease or risk factor is proportionate to burden or attributable risk, respectively. Our results therefore have implications for national government, local government, and health services in England.

For national government, the quantification by the GBD study of the continuing burden of preventable ill health more than justifies recent calls for a "radical upgrade in prevention and public health".<sup>3</sup> National government will also be concerned that improvements in premature mortality in England are diminished by increases in deaths from liver disease, by contrast with the declines seen in similar countries such as France.

For English local authorities in their new role as leaders for local population health, the most striking findings relate to inequalities, not only the size and nature of the effect of deprivation on health but also that the gap between the most deprived and least deprived areas of England shows little sign of reducing. The GBD 2013 results underline the fact that local authorities in the more disadvantaged regions of England are not the only ones that need to tackle the effects of deprivation, and to make this task a priority.

For health services, one important implication of our results is the scale of the increasing level of disability and, especially, the growth of multimorbidity. This new form of demand requires new and more integrated models of care spanning health and social services that respond to the specific needs and circumstances of individual patients. The other important implication for health services is that about 40% of their workload is potentially preventable, yet the proportion of health expenditure directed at prevention, although hard to estimate reliably, is probably closer to 4%.<sup>64</sup>

Combining GBD results with data on expected trends in population structure and risk factors could be used to anticipate future disease burden and thereby provide an important input to economic models and forecasts. This will be addressed in future GBD work. The importance of prevention argues for robust, standardised, comparative assessments of the cost-effectiveness of different public

health policies to aid decision making, akin to those used in England for health technologies. Such assessments are likely to highlight the need for more empirical evidence of the effectiveness of specific preventive approaches. Finally, there are substantial gaps in routine and survey data on the prevalence of morbidity at the subnational level that could be addressed.

If the levels of health seen in the best performing English regions could be achieved in the worst performing regions, England would have a level of overall burden of disease as low as any country with a developed post-industrial economy. This interpretation provides a strong argument for implementing policies for effective prevention and treatment, but these policies must also be designed to reduce inequalities associated with the socioeconomic determinants of health.

#### Contributors

JNN, ADMB, CJLM, TV, JDS, SMB, DC, and MMC prepared the first and subsequent drafts and finalised the report on the basis of feedback from all other authors and reviewers. AJH, CG, and MMcK contributed to the writing of more than one draft. HR, KSB, CEGB, TSB, SC, PE, FG, MAG, DJG, HH, RAL, HM, CRN, PS, AT, JV, and ADW contributed to the writing about specific diseases, conditions, or topics. ACJD, CJLM, HW, MN, JCS, and AJH were involved in the origination and development of the concept. ACJD, CJLM, DD, KJF, HW, MN, MHF, SLO, RMB, JDS, RE, SMB, DC, MMC, MSF, and AES were involved in the development and execution of the GBD 2013 methodology. MHF, SLO, RMB, JDS, AJH, DFJF, SMB, CEGB, TSB, DC, MMC, KJL, AJM-J, and FEM provided data. AJH, DFJF, IA, MSF, FEM, KR, and AES prepared the data. DD, KJF, AJH, DFJF, MSF, FEM, and AES analysed the data. JNN, ADMB, CJLM, DD, KJF, MHF, SLO, RMB, JCS, AJH, DFJF, RE, CG, KSB, CEGB, AJM-J, and ACJD were involved in data interpretation. DD, KJF, MHF, RMB, TV, JDS, JCS, AJH, DFJF, CG, MMcK, HR, IA, HRA, AB, SMB, CEGB, NGB, DC, RC, MMC, MKD, PE, ME, KAF, MSF, TF, FG, MAG, BMH, RJH, SIH, HJL, KJL, RL, AJM-J, FEM, MEM, NP, FBP, DP, KR, AR, PS, AES, IS, LS, CDAW, ADW, and ACJD reviewed and commented extensively on several drafts. HR, RA, AB, DAB, EB, KSB, RRB, CEGB, TSB, MB, SC, RC, CC, JAC, PID, DJG, HH, RAL, AJM-J, HM, MEM, NP, AT, JV, HCW, and ADW reviewed and commented extensively on specific diseases, disorders, or topics. JCS, AJH, DFJF, RE, CG, MMcK, and HM responded extensively to peer-reviewers' comments. JCS, AJH, DFJF, MMcK, HR, IA, HRA, EB, KSB, RRB, CEGB, NGB, TSB, RC, MKD, PE, ME, RJH, RAL, WM, MEM, CRN, DP, HCW, CDAW, ADW, and ACJD are members of the GBD England Expert or Steering Group.

#### Declaration of interests

JNN, JCS, AJH, DFJF, RE, CG, FG, KAF, BMH, AT, and ACJD were employed by Public Health England during the study. ADMB is a Wellcome Trust-funded Research Training Fellow. CG reports personal fees from Meteos outside the submitted work. DJG is a member of the England National Suicide Prevention Strategy Advisory Group. KJL reports personal fees from WHO during the study and personal fees from WHO outside the submitted work. LS reports grants from the Wellcome Trust during the study, grants from the Wellcome Trust, Medical Research Council, and National Institute for Health Research outside the submitted work, and personal fees from GlaxoSmithKline outside the submitted work. ADW is the Chair of the Global Alliance for Musculoskeletal Health of the Bone and Joint Decade. All other authors declare no competing interests.

#### Acknowledgments

We thank Sonya Clark for project support to the Public Health England GBD team, Kelly Bienhoff for project management for the Institute for Health Metrics and Evaluation team, and Erica Ison (Better Value Healthcare, on behalf of Public Health England) for editing and version control of the manuscript. We are grateful for the care taken by the peer reviewers and for their many helpful comments and suggestions.

## References

- 1 Murray CJL, Richards MA, Newton JN, et al. UK health performance: findings of the Global Burden of Disease Study 2010. *Lancet* 2013; **381**: 997–1020.
- 2 Greer SL. Devolution and divergence in UK health policies. *BMJ* 2008; **337**: a2616.
- 3 England NHS. Five year forward view. 2014. <http://www.england.nhs.uk/ourwork/futurehhs/> (accessed Aug 24, 2015).
- 4 Naghavi M, Wang H, Lozano R, and the GBD 2013 Mortality and Causes of Death Collaborators. Global, regional and national levels of age-specific mortality and 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 2015; **385**: 117–71.
- 5 Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disabilities for 301 acute and chronic diseases and injuries for 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 2015; **386**: 743–800.
- 6 Global Burden of Disease Study 2013 Collaborators. Global, regional, and national comparative risk assessment of 76 behavioural, environmental, occupational, and metabolic risks or clusters of risks in 188 countries 1990–2013: a systematic analysis for the Global Burden of Disease study 2013. *Lancet* 2015; published online Sept 11. [http://dx.doi.org/10.1016/S0140-6736\(15\)00128-2](http://dx.doi.org/10.1016/S0140-6736(15)00128-2).
- 7 GBD 2013 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. *Lancet* 2015; published online Aug 27. [http://dx.doi.org/10.1016/S0140-6736\(15\)61340-X](http://dx.doi.org/10.1016/S0140-6736(15)61340-X).
- 8 Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012; **380**: 2163–96.
- 9 Murray CJL, Ezzati M, Flaxman AD, et al. GBD 2010: design, definitions, and metrics. *Lancet* 2012; **380**: 2063–66.
- 10 Office for National Statistics. Statistical Bulletin. Super output area population estimates, mid-2011 (census based). [http://www.ons.gov.uk/ons/dcp171778\\_302853.pdf](http://www.ons.gov.uk/ons/dcp171778_302853.pdf) (accessed Aug 24, 2015).
- 11 McLennan D, Barnes H, Noble M, Davies J, Garratt E. The English indices of deprivation 2010. Technical report. London: Department for Communities and Local Government, 2011. [https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/6320/1870718.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/6320/1870718.pdf) (accessed Aug 24, 2015).
- 12 Adams J, White M. Removing the health domain from the Index of Multiple Deprivation 2004—effect on measured inequalities in census measure of health. *J Public Health (Oxf)* 2006; **28**: 379–83.
- 13 Wang H, Dwyer-Lindgren L, Lofgren KT, et al. Age-specific and sex-specific mortality in 187 countries, 1970–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012; **380**: 2071–94.
- 14 Murray CJL, Rajaratnam JK, Marcus J, Laakso T, Lopez AD. What can we conclude from death registration? Improved methods for evaluating completeness. *PLoS Med* 2010; **7**: e1000262.
- 15 Naghavi M, Makela S, Foreman K, O'Brien J, Pourmalek F, Lozano R. Algorithms for enhancing public health utility of national causes-of-death data. *Popul Health Metr* 2010; **8**: 9.
- 16 Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012; **380**: 2095–128.
- 17 Ahern RM, Lozano R, Naghavi M, Foreman K, Gakidou E, Murray CJ. Improving the public health utility of global cardiovascular mortality data: the rise of ischemic heart disease. *Popul Health Metr* 2011; **9**: 8.
- 18 Foreman KJ, Lozano R, Lopez AD, Murray CJ. Modeling causes of death: an integrated approach using CODEm. *Popul Health Metr* 2012; **10**: 1.
- 19 Office for National Statistics. Statistical Bulletin. Suicides in the United Kingdom, 2012 registrations. 2014. [http://www.ons.gov.uk/ons/dcp171778\\_351100.pdf](http://www.ons.gov.uk/ons/dcp171778_351100.pdf) (accessed Aug 24, 2015).
- 20 Health Survey for England—2013. Dec 10, 2014. <http://www.hscic.gov.uk/catalogue/PUB16076> (accessed Feb 26, 2015).
- 21 Matthews FE, Arthur A, Barnes LE, et al. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. *Lancet* 2013; **382**: 1405–12.
- 22 Salomon JA, Haagsma JA, Davis ACJ, et al. Disability weights for the Global Burden of Disease 2013 Study. *Lancet Glob Health* (in press).
- 23 Haagsma JA, de Noordhout CM, Polinder S, et al. Assessing disability weights based on the responses of 30 660 people from four European countries. *Popul Health Metr* 2015; **13**: 10.
- 24 Preston S, Heuveline P, Guillot M. Demography: measuring and modeling population processes, 1st edn. Malden, MA: Wiley-Blackwell, 2000.
- 25 Beltrán-Sánchez H, Preston SH, Canudas-Romo V. An integrated approach to cause-of-death analysis: cause-deleted life tables and decompositions of life expectancy. *Demogr Res* 2008; **19**: 1323–50.
- 26 Salomon JA, Wang H, Freeman MK, et al. Healthy life expectancy for 187 countries, 1990–2010: a systematic analysis for the Global Burden Disease Study 2010. *Lancet* 2012; **380**: 2144–62.
- 27 Murray CJL, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012; **380**: 2197–223.
- 28 Gelman A. Analysis of variance—why it is more important than ever. *Ann Stat* 2005; **33**: 1–53.
- 29 National End of Life Care Intelligence Network. Deaths from Alzheimer's disease, dementia and senility in England. 2010. [http://www.endoflifecare-intelligence.org.uk/resources/publications/deaths\\_from\\_alzheimers](http://www.endoflifecare-intelligence.org.uk/resources/publications/deaths_from_alzheimers) (accessed Aug 24, 2015).
- 30 Office for National Statistics. Mortality in the United Kingdom, 2010. Jan 20, 2012. [http://www.ons.gov.uk/ons/dcp171780\\_251270.pdf](http://www.ons.gov.uk/ons/dcp171780_251270.pdf) (accessed Aug 24, 2015).
- 31 Office for National Statistics. Statistical Bulletin. National life tables, United Kingdom, 2011–2013. Sept 25, 2014. <http://www.ons.gov.uk/ons/rel/lifetables/national-life-tables/2011-2013/stb-uk-2011-2013.html> (accessed Aug 24, 2015).
- 32 Green M. Death in England and Wales: using a classificatory approach for researching mortality. PhD thesis, University of Sheffield, 2013.
- 33 Green MA, Vickers D, Dorling D. A neighbourhood level mortality classification of England and Wales, 2006–2009. *Health Place* 2014; **30**: 196–204.
- 34 Rasulo D, Bajekal M, Yar M. Inequalities in health expectancies in England and Wales—small area analysis from the 2001 census. *Health Stat Q* 2007; **34**: 35–45.
- 35 Office for National Statistics. Statistical bulletin. Experimental statistics. Inequality in disability-free life expectancy by area deprivation: England, 2003–06 and 2007–10. [http://www.ons.gov.uk/ons/dcp171778\\_319481.pdf](http://www.ons.gov.uk/ons/dcp171778_319481.pdf) (accessed Aug 24, 2015).
- 36 Bennett JE, Li G, Foreman K, et al. The future of life expectancy and life expectancy inequalities in England and Wales: Bayesian spatiotemporal forecasting. *Lancet* 2015; **386**: 163–70.
- 37 Rienzo C. Migrants in the UK labour market: an overview. Aug 28, 2012. <http://storage0.dms.mpinteractiv.ro/media/1/186/3927/10538667/2/briefing-migrants-the-uk-labour-market-0.pdf> (accessed Aug 24, 2015).
- 38 Bongaart J. Trends in causes of death in low-mortality countries: implications for mortality projections. *Popul Dev Rev* 2014; **40**: 189–212.
- 39 Williams R, Aspinall R, Bellis M, et al. Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. *Lancet* 2014; **384**: 1953–97.
- 40 Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. *Alzheimers Dement* 2013; **9**: 63–75.
- 41 Holland D, Desikan RS, Dale AM, McEvoy LK, and the Alzheimer's Disease Neuroimaging Initiative. Rates of decline in Alzheimer disease decrease with age. *PLoS One* 2012; **7**: e42325.
- 42 Rocca WA, Petersen RC, Knopman DS, et al. Trends in the incidence and prevalence of Alzheimer's disease, dementia, and cognitive impairment in the United States. *Alzheimers Dement* 2011; **7**: 80–93.

- 43 Hoy DG, Smith E, Cross M, et al. Reflecting on the global burden of musculoskeletal conditions: lessons learnt from the Global Burden of Disease 2010 Study and the next steps forward. *Ann Rheum Dis* 2014; **74**: 4–7.
- 44 Kessler D, Bennenwith O, Lewis G, Sharp D. Detection of depression and anxiety in primary care: follow up study. *BMJ* 2002; **325**: 1016–17.
- 45 Davidson JR, Feltner DE, Dugar A. Management of generalized anxiety disorder in primary care: identifying the challenges and unmet needs. *Prim Care Companion J Clin Psychiatry* 2010; **12**: pii PCC.09r00772.
- 46 Buszewicz MJ, Chew-Graham C. Improving the detection and management of anxiety disorders in primary care. *Br J Gen Pract* 2011; **61**: 489–90.
- 47 van Zoonen K, Buntrock C, Ebert DD, et al. Preventing the onset of major depressive disorder: a meta-analytic review of psychological interventions. *Int J Epidemiol* 2014; **43**: 318–29.
- 48 National Diabetes Audit 2012–2013. Report 1. Care processes and treatment targets. Oct 2, 2014. <http://www.hscic.gov.uk/catalogue/PUB14970> (accessed Aug 28, 2015).
- 49 Bajekal M, Scholes S, Love H, et al. Analysing recent socioeconomic trends in coronary heart disease mortality in England, 2000–2007: a population modelling study. *PLoS Med* 2012; **9**: e1001237.
- 50 He FJ, Brinsden HC, MacGregor GA. Salt reduction in the United Kingdom: a successful experiment in public health. *J Hum Hypertens* 2014; **28**: 345–52.
- 51 Fleming KM, Aithal GP, Solaymani-Dodaran M, Card TR, West J. Incidence and prevalence of cirrhosis in the United Kingdom, 1992–2001: a general population-based study. *J Hepatol* 2008; **49**: 732–38.
- 52 Ratib S, West J, Crooks CJ, Fleming KM. Diagnosis of liver cirrhosis in England, a cohort study, 1998–2009: a comparison with cancer. *Am J Gastroenterol* 2014; **109**: 190–98.
- 53 Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979–94. *Lancet* 1997; **350**: 1142–43.
- 54 Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. *Gastroenterology* 2004; **127** (suppl 1): S5–16.
- 55 Leon DA, McCambridge J. Liver cirrhosis mortality rates in Britain from 1950 to 2002: an analysis of routine data. *Lancet* 2006; **367**: 52–56.
- 56 Link BG, Phelan J. Social conditions as fundamental causes of disease. *J Heal Soc Behav* 1995; **80**–94.
- 57 Ritchie K, Carrière I, Ritchie CW, Berr C, Artero S, Ancelin M-L. Designing prevention programmes to reduce incidence of dementia: prospective cohort study of modifiable risk factors. *BMJ* 2010; **341**: c3885.
- 58 Lee Y, Back JH, Kim J, et al. Systematic review of health behavioral risks and cognitive health in older adults. *Int Psychogeriatr* 2010; **22**: 174–87.
- 59 Engelhart MJ, Geerlings MI, Ruitenberg A, et al. Dietary intake of antioxidants and risk of Alzheimer disease. *JAMA* 2002; **287**: 3223–29.
- 60 Haan MN, Wallace R. Can dementia be prevented? Brain aging in a population-based context. *Annu Rev Public Health* 2004; **25**: 1–24.
- 61 Dai Q, Borenstein AR, Wu Y, Jackson JC, Larson EB. Fruit and vegetable juices and Alzheimer's disease: the Kame Project. *Am J Med* 2006; **119**: 751–59.
- 62 Smith AD, Yaffe K. Dementia (including Alzheimer's disease) can be prevented: statement supported by international experts. *J Alzheimers Dis* 2014; **38**: 699–703.
- 63 Office for National Statistics. Suicides in the United Kingdom, 2013 registrations. 2015. [http://www.ons.gov.uk/ons/dcp171778\\_395145.pdf](http://www.ons.gov.uk/ons/dcp171778_395145.pdf) (accessed Aug 24, 2015).
- 64 Butterfield R, Henderson J, Scott R. Public health and prevention, expenditure in England. Health England Report No. 4. London: Department of Health, 2009.